EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Prevention of severe immune‐related colitis caused by combined immune checkpoint inhibition using vedolizumab: A case report

J Jochmann iD, A Fink, A Stella, R Feldmann, L Kramer, C Posch

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19028 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von J Jochmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Klinik Hietzing, Vienna, Austria. Hauptthemen laut MEDLINE: Colitis, Colitis, Ulcerative. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dear Editor, To date, combined immune checkpoint inhibition (CPI) with PD1 and CTLA4 antibodies offers the most effective treatment option for patients with metastatic melanoma. However, the combination of CPIs comes with a significant rate of Grades 3 and 4 immunerelated adverse events (irAEs) including colitis amongst others. In severe cases, treatment must be paused or completely abandoned. Additionally, immunosuppressive/immunomodulatory treatment with steroids, mycophenolate mofetil and infliximab may be required. In rare cases, even combined immunosuppression is insufficient to control side effects.1– 3 The European Society of Medical Oncology guidelines highlight vedolizumab, an IgG1 monoclonal antibody directed against α4β7 integrin, which is approved for the treatment of inflammatory bowel disease, as an option for the treatment of immunotherapyrelated colitis.4 In the following case, we describe the prophylactic use of vedolizumab in a patient with metastatic melanoma in combination with dual CPI, successfully preventing recurrent ircolitis. In 2020, a 48yearold woman with metastatic acral melanoma T4aN1M0 (initial tumour thickness 4.3 mm) presented to our clinic. The patient had previously received 13 cycles of immune monotherapy (pembrolizumab) plus radiation treatment for lymph node metastases. Received: 23 January 2023 | Accepted: 8 March 2023

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisColitis, UlcerativeHumansImmune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Substanzen

vedolizumabImmune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Klinik Hietzing, Vienna, Austria.
  • Department of Gastroenterology, Klinik Hietzing, Vienna, Austria.
  • Faculty of Medicine, Sigmund Freud University Vienna, Vienna, Austria.
  • Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.

ORCID-Profile: J Jochmann

Zitieren

APA

Jochmann, J., Fink, A., Stella, A., Feldmann, R., Kramer, L., & Posch, C. (2023). Prevention of severe immune‐related colitis caused by combined immune checkpoint inhibition using vedolizumab: A case report. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19028

Vancouver

Jochmann J, Fink A, Stella A, Feldmann R, Kramer L, Posch C. Prevention of severe immune‐related colitis caused by combined immune checkpoint inhibition using vedolizumab: A case report. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19028

BibTeX
@article{Jochmann2023,
  author = {Jochmann, J and Fink, A and Stella, A and Feldmann, R and Kramer, L and Posch, C},
  title = {Prevention of severe immune‐related colitis caused by combined immune checkpoint inhibition using vedolizumab: A case report},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19028}
}
Kostenlos starten →